This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0314U for DecisionDx® DiffDx™ Melanoma from Castle Biosciences Inc. Using formalin–fixed paraffin–embedded (FFPE) tissue from a skin lesion suspicious for cutaneous (skin) melanoma, the test uses reverse–transcription polymerase chain reaction (RT–PCR) gene expression profiling to analyze the specimen for the activity of 35 genes (32 content and three housekeeping). An algorithmic analysis of the findings categorizes the lesion as benign, intermediate, or malignant.
For clinical responsibility, terminology, tips and additional info
start codify free trial.